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The adaptive immune system in vertebrates consists of highly diverse immune receptors to mount
specific responses against a multitude of pathogens. A central feature of the adaptive immune
system is the ability to form a memory to act more efficiently in future encounters with similar
pathogens. However, memory formation especially in B-cells is one of the least understood cell fate
decisions in the immune system. Here, we present a framework to characterize optimal strategies to
store memory in order to maximize the utility of immune response to counter evolving pathogens
throughout an organism’s lifetime. To do so, we have incorporated the kinetics and energetics of
memory response as ingredients of non-equilibrium decision-making between an adaptive exploration
to mount a specific and novel response or exploitation of existing memory that can be activated
rapidly yet with a reduced specificity against evolved pathogens. To achieve a long-term benefit
for the host, we show that memory generation should be actively regulated and dependent on
immune receptors’ affinity, with a preference for cross-reactive receptors with a moderate affinity
against pathogens as opposed to high affinity receptors— a recipe that is consistent with recent
experimental findings [1, 2]. Moreover, we show that the specificity of memory should depend on
the organism’s lifespan, and shorter-lived organisms with fewer pathogenic encounters throughout
their lifetime should store more cross-reactive memory. Overall, our framework provides a baseline
to gauge the efficacy of immune memory formation in light of an organism’s coevolutionary history
with pathogens.
I. INTRODUCTION
Adaptive immunity in vertebrates develops during the
lifetime of an organism to battle a multitude of evolving
pathogens. The central actors in our adaptive immune
system are diverse B- and T-cells, whose unique surface
receptors are generated through genomic rearrangement,
mutation, and selection [3]. The diversity of receptors
allows the immune system to mount specific responses
against diverse pathogens. B-cell receptors (BCRs) in
particular can specialize through a process of affinity
maturation, which is a form of somatic Darwinian evolu-
tion within an individual to enhance the affinity of BCRs
to pathogens. During affinity maturation, B-cells aggre-
gate in lymph nodes to form germinal centers, where they
undergo somatic hypermutation, compete for resources
like T-cell help, and are selected based on their binding
affinity to pathogens. Several rounds of mutation and se-
lection can increase binding affinities of receptors up to
10-1000 fold [4, 5].
Beside receptor diversity, immune cells also differenti-
ate and specialize to take on different roles. Importantly,
both B- and T-cells can differentiate into different forms
of memory cells (e.g. IgG or IgM memory in B-cells,
and CD4 or CD8 memory in T-cells) [6, 7]. Memory
∗correspondence should be addressed to Armita Nourmohammad:
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is central to adaptive immunity through which our im-
mune system can be trained during an infection or by
vaccination against a pathogen to respond more readily
upon re-exposure [3]. Memory responses are highly effi-
cient since memory cells can be reactivated faster than
na¨ıve cells and can mount a more robust response to an
infection [8–11].
Memory generation is a form of cell fate decision in the
immune system, which can occur at different stages of an
immune response. In B-cells, activated na¨ıve cells can dif-
ferentiate into antibody-secreting long-lived plasma cells
or a T-cell independent un-hypermutated memory cell,
or they can initiate a germinal center [12]. B-cells that
enter germinal centers differentiate during affinity mat-
uration into high affinity plasma cells, which act as an-
tibody factories, or T-cell dependent long-lived memory
cells that circulate in the blood for antigen surveillance;
see schematic Fig. 1.
The basis for differentiation of B-cells into memory,
especially during affinity maturation, is among the least
understood in cell fate decision-making in the immune
system [12]. A long-standing view was that memory is
continuously produced during affinity maturation [13].
Memory receptors often have lower affinity compared to
plasma cells [14], and therefore, if memory were to be
generated continuously it should be able to proliferate
without strong affinity dependent selection [4, 12]. How-
ever, recent experiments indicate that memory differen-
tiation is highly regulated [1, 2, 15–17], reflecting a tem-
poral switch in germinal centers that preferentially pro-
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FIG. 1: Immune memory or na¨ıve response upon infection. (A) Schematic shows affinity maturation in germinal
centers(right), where B-cell receptors acquire mutations and undergo selection, resulting in an increase in their affinity to an
antigen (from light to dark receptors), indicated by the sharpening of receptors’ affinity profiles (on left). (B) Affinity profile
Eα,θ(r, υ) ∼ α exp[−(αd)θ] of a receptor r is shown in orange as a function of the distance d = υ∗r − υ in the antigenic shape
space, between the receptor’s cognate antigen υ∗r (orange) and another target υ (red). The affinity of a receptor decays with
increasing distance between targets and its cognate antigen. The antigenic range over which a receptor is reactive inversely
depends on its specificity α. The shape of the binding profile is tuned by the factor θ, here shown for θ = 2. (C) Upon
infection, the immune system can initiate a novel response (top) or a memory response (bottom). A novel B-cell response could
involve affinity maturation to generate memory or high affinity plasma cells (pink) that can secrete antibodies to battle the
pathogen. A novel response can take 1-2 weeks, during which pathogen can replicate within a host and a patient can show
symptoms from the disease (top). If the host carries memory from a previous infection or vaccination (bottom), the immune
system can robustly and rapidly activate a memory response to battle the infection. Cross-reactive memory can be activated
against slightly evolved forms of an antigen (dark red), drifted from to the primary infection (orange).
duces memory at early stages and plasma at later stages
of affinity maturation [16]. Importantly, it has been sug-
gested that this regulation is done through a T-cell de-
pendent pathway in germinal centers, in which T-cell help
suppresses the expression level of the transcription fac-
tor Bach2, whose abundance predisposes B-cells to be-
come memory [1, 2]. This active regulation introduces
an affinity-dependent cell fate decision, as B-cells with
lower affinities attract less T-cell help and hence, main-
tain a higher level of Bach2, leading to a preferential se-
lection of low-affinity cells to the memory compartment.
Low affinity memory may be at a disadvantage in
mounting a protective immune response since immune-
pathogen recognition is largely determined by the bind-
ing affinity between an immune receptor and antigenic
epitopes. On the other hand, as in most molecular inter-
actions, immune-pathogen recognition is cross-reactive,
which would allow memory receptors to recognize slightly
evolved forms of the antigen, in response to which they
were originally generated. Therefore, the long-term util-
ity of a memory cell depends on balancing the recep-
tor’s affinity and cross-reactivity to protect against mod-
erately evolved forms of a pathogen [18, 19].
The program for differentiation of immune cells to
memory should be viewed in light of the utility of mem-
ory during an organism’s lifetime. Here, we present a
theoretical framework that incorporates the kinetics and
energetics of memory responses as ingredients of a non-
equilibrium decision-making process to choose a mem-
ory or a novel response upon re-exposure to evolving
pathogens. We quantify the characteristics of memory,
including its relative cross-reactivity and speed of activa-
tion, that would confer the highest long-term utility for
the immune system in countering pathogens with differ-
ent evolutionary rates. We propose that the hard-wired
affinity-dependent regulatory measures during differenti-
ation of memory could be understood as a way to op-
timize the long-term utility of immune memory against
evolving pathogens.
Indeed, previous work on theoretical modeling of cel-
lular differentiation together with experiments has been
instrumental in understanding immune memory gener-
ation; e.g. see reviewed work in [20, 21]. For exam-
ple, mechanistic models have indicated the importance
of signal integration at the cellular level [22] and the rel-
evance of stochastic effects at the population level [23],
to explain heterogeneous cell fate decisions for the gen-
eration of memory. Our statistical framework, on the
other hand, aims to characterize high-level features for
an optimal memory strategy, without relying on mech-
anistic details of the underlying process, some of which
are at least partially unknown [24, 25]. In the case of the
immune system, statistical models have provided an intu-
ition for how an immune repertoire should be organized
to optimally counter diverse pathogens [19, 26–29]. In a
similar fashion, optimal memory strategies identified by
our model provide a baseline to gauge the performance
of real immune systems in storing and utilizing memory.
3II. MODEL
Kinetics of na¨ıve and memory immune response.
Upon encountering a pathogen, the adaptive immune
system mounts a response by activating the na¨ıve
repertoire (i.e., a novel response) and/or by triggering
previously stored immune receptors in the memory
compartment. A memory receptor often shows a re-
duced affinity in interacting with an evolved form of
the pathogen. Nonetheless, memory plays a central
role in protecting against re-infections since even a
suboptimal memory can be kinetically more efficient
than a na¨ıve response, both in B-cells [10] and T-
cells [30, 31]. First, memory cells are fast responders
and initiate cell division about τ0 ≈ 1 − 2 days before
na¨ıve cells [9, 10, 32]. Second, the number of memory
cells that are recruited to proliferate and differentiate to
effector cells is b ≈ 2− 3 times larger than the number of
na¨ıve cells [9, 10]. Once recruited however, memory and
na¨ıve cells have approximately a similar doubling time
of about t1/2 ≈ 0.5−2 days [9, 33]. Putting these kinetic
factors together, we can define an effective deliberation
time τ for the na¨ıve population to reach an activity
level (i.e., a population size) comparable to the memory.
Assuming an exponential growth during early stages
of memory and na¨ıve proliferation, the deliberation
time can be estimated in terms of the kinetic factors
by τ = τ0 + t1/2 ln b/ ln 2 and it is within a range of
τ ≈ 1.5− 5 days; see Fig. 1.
Energetics of immune recognition. Recognition of a
pathogen by an immune receptor is mediated by the affin-
ity of the molecular interactions E(r, υ) between the im-
mune receptor r and the antigenic epitope υ from the
pathogen. As in most molecular interactions, immune-
pathogen recognition is cross-reactive: each immune re-
ceptor can interact with several antigens and each antigen
can be recognized by more than one immune receptor;
see Fig. 1. We describe immune-pathogen recognition in
an immune shape space [26], which reflects the intuition
that specific protein-protein interactions are determined
by the 3D structure of the interface, i.e., their comple-
mentary shapes. Receptors located near each other in
shape space can recognize similar antigens, and in the
complementary space, antigens that are close to each
other can be recognized by the same immune receptor.
We assume that each immune receptor r has a cognate
antigen υ∗r against which it has the highest affinity. We
express the binding affinity between a receptor r and an
arbitrary target antigen υ in terms of the antigenic dis-
tance dr(υ) = ‖υ − υ∗r‖ between the receptor’s cognate
antigen υ∗r and the target υ: E(r, υ) ≡ E(dr(υ)). This
distance-dependent binding affinity is measured with re-
spect to the affinity of unspecific antigen-receptor inter-
actions, sufficient to trigger a generic na¨ıve response.
Physico-chemical constraints in protein structures can
introduce a tradeoff between immune receptors’ affinity
and cross-reactivity (i.e., ability to equally react to multi-
ple targets). Although we lack a systematic understand-
ing of these structural constraints, affinity-specificity
tradeoffs have been reported repeatedly for B-cells and
antibodies. Prior to affinity maturation, the structure of
na¨ıve receptors is relatively flexible whereas hypermuta-
tions often reconfigure the active sites of a receptor and
make them more specific so that they match their tar-
get antigens like a lock and key [34, 35]. As a result, the
IgM class of antibodies, which are the first line of defense
in B-cell response, often have low affinities, yet they are
cross-reactive and can recognize mutated forms of the
same epitope. On the other hand, the high affinity IgG
class of antibodies, which are the late outcomes of affin-
ity maturation in germinal centers, have higher affinities
but bind very specifically to their cognate antigen [35].
Broadly neutralizing antibodies (bNAbs) are exceptions
to this rule since they often have high potency and can
react to a broad range of viral strains. However, bNAbs
often react to vulnerable regions of a virus where escape
mutations are very deleterious [36]. In other words, the
majority of bNAbs are not cross-reactive per se, but they
are exceptionally successful in targeting conserved epi-
topes in otherwise diverse viral strains. Nevertheless, an
affinity-specificity tradeoff has been reported for a bNAb
against the hemagglutinin epitope of influenza [37].
We use a simple functional form to qualitatively cap-
ture the tradeoff between cross-reactivity and affinity
of antigen-receptor binding interactions: We assume
that the binding affinity of a receptor r to an anti-
gen υ depends on the antigenic distance dr(υ) = ‖υ −
υ∗r‖ through a kernel with a specificity factor α and
a shape factor θ such that, E(r, υ) ≡ Eα,θ(dr(υ)) ∼
α exp[− (α‖υ − υ∗r‖)θ], with θ ≥ 0. This affinity func-
tion defines a receptor’s binding profile over the space of
antigens. The width of this binding profile is set by the
inverse of the specificity factor 1/α (Fig. 1). As specificity
α increases (or cross-reactivity 1/α decays), the binding
affinity profile sharpens and binding becomes more re-
strictive to antigens closer to the receptor’s cognate anti-
gen. Moreover, the absolute strength of binding to the
cognate antigen (i.e., a receptor’s maximum affinity) in-
creases with specificity α, resulting in a tradeoff between
affinity and cross-reactivity. The parameter θ tunes the
shape of the receptor’s binding profile Eα,θ(dr(υ)), re-
sulting in a flat function (i.e., no tradeoff) for θ = 0, a
double-sided exponential function for θ = 1, a Gaussian
(bell-curve) function for θ = 2, and top-hat functions for
θ  2.
Structural constraints and molecular features of
protein receptors define a bound on the minimum
cross-reactivity or equivalently, a maximum specificity
αmax, achievable by a receptor. Using this bound, we
define rescaled specificity αˆ ≡ α/αmax to characterize
the energetics of an immune response in a dimensionless
form.
Immune response to evolving pathogens. Upon pri-
mary infection (i.e., an encounter with a novel pathogen)
4na¨ıve immune receptors with moderate affinity are ac-
tivated to develop a specific response through affinity
maturation (Fig. 1). Since the na¨ıve repertoire is diverse
enough to contain receptors of moderate affinity against
different antigens, we assume that the affinity of respon-
sive na¨ıve receptors, and hence, the strength of a pri-
mary immune response to be approximately the same for
all pathogens. This simplification becomes less accurate
as the immune system ages and the supply of effective
receptors become more scarce.
Following a na¨ıve response to a primary infection and
the subsequent affinity maturation, the immune system
stores memory cells with an enhanced affinity to use them
against future infections [3]; see Fig. 1. Therefore, the
cognate antigen υ∗rm for a given memory receptor rm is
an epitope derived from the primary infection that led
to the formation of memory, which we denote by υ0 with
a subscript that indicates round of infection. Thus, the
binding profile Eα,θ(rm, υ) of the memory receptor rm is
peaked around the primary antigenic epitope υ∗rm = υ0
(Fig. 1). As pathogens evolve globally to escape the im-
mune challenge, drugs or vaccination, they drift away
from the primary antigen in antigenic space. We model
this antigenic shift as a diffusion in shape space whereby
a reinfecting pathogen at the ith round of infection υi
is on average at a distance δ =
√〈‖υi − υi−1‖2〉 from
the previous infection υi−1. This antigenic shift is pro-
portional to the rate of pathogen evolution ζυ and the
average time between infections ∆t = ti− ti−1, such that
δ ∝ ζυ
√
∆t. A cross-reactive memory can mount a re-
sponse to an evolved antigen, yet with a reduced affinity
that decays with antigenic shift; see Fig. 1. It should
be noted that the minimum level of receptor’s cross-
reactivity (or maximum specificity) (αmax)
−1 defines a
natural scale against which we can measure antigenic di-
vergence δ and hence, form a dimensionless measure of
antigenic divergence δˆ ≡ δ/(αmax)−1.
Immune-pathogen recognition depends both on the
binding affinity Eα,θ(r, υ) and the encounter rate γυ(t)
between an immune receptor r and the antigen υ at
a given time t. The encounter rate γυ(t) depends on
the abundance of the antigen and the immune receptor,
and hence, can vary during an infection within a host.
The probability that a receptor r encounters and binds
to an antigen υ in a short time interval [t, t + dt] can
be expressed by, ρ(r, υ, t)dt = γυ(t)Eα,θ(r, υ)dt; a simi-
lar notion of encounter rate has been previously used in
ref. [19]. A memory response in an individual is triggered
through recognition of an antigen by a circulating mem-
ory receptor. If no such recognition occurs during the
deliberation time τ ≈ 1.5 − 5 days, the immune system
initiates a na¨ıve response. Therefore, the probability that
an antigen is recognized through a novel na¨ıve response
P (0)
recog.
can be expressed as the probability of the antigen
not being recognized 1 − P (m)
recog.
by an available memory
receptor rm over the deliberation period τ ,
P (0)recog.(υ) = 1− P (m)recog.(rm, υ)
= e−
∫ τ
0
ρ(υ,t)dt = e−Eα,θ(rm,υ)Γ(υ,τ) (1)
where Γ(υ, τ) =
∫ τ
0
γυ(t)dt is the expected number
of pathogenic encounters over the deliberation time τ
and depends on the accumulated pathogenic load, as
pathogens proliferate in the absence of an effective mem-
ory prior to a na¨ıve response. Here, we have assumed that
the affinity of the memory receptor does not change over
the response time, which is a simplification since memory
receptor can undergo limited affinity maturation [38, 39].
To further simplify, we also assume that the accumu-
lated pathogenic load is independent of the type of the
pathogen Γ(υ, τ) ≡ Γ(τ). As pathogens evolve away from
the primary infector, the binding affinity Eα,θ(rm, υ) of
the stored memory receptor rm, and hence, the probabil-
ity to mount a memory response P
(m)
recog.(rm, υ, τ) decays.
The deliberation time prior to a novel response pro-
vides a window for memory to react with an antigen and
mount an immune response by initiating an irreversible
cascade of downstream events. Although initiation
of this pathogenic recognition can be modeled as an
equilibrium process, the resulting immune response is a
non-equilibrium and an irreversible process, the details
of which are not included in our model.
Decision-making to mount a memory or na¨ıve re-
sponse. The decision to mount a na¨ıve or a mem-
ory response depends on the energetics and the kinetics
of the immune machinery, including the cross-reactivity
of memory to recognize evolved pathogens and the de-
liberation time to mount a na¨ıve response upon infec-
tion — we refer to these choices as memory strategies.
We expect that the biochemical machinery involved in
making this decision upon an infection has been fine-
tuned and selected over evolutionary time scales in order
to utilize immune memory and mount an effective re-
sponse against evolving pathogens. Here, we introduce
a decision-making framework to identify optimal mem-
ory strategies for the adaptive immune system to achieve
its highest long-term utility. This framework does not
assume that the immune system, as we know it, should
be optimized, rather it defines a baseline against which
memory strategies of the actual immune system could be
gauged.
In the theory of decision-making, a rational decision-
maker chooses between two possible actions a ∈
{na¨ıve, memory} each contributing a utility Ua. The ac-
tion of a rational decision-maker should follow an optimal
distribution Q(a), which maximizes the expected utility
while satisfying the constraints in processing new infor-
mation, e.g. due to prior preferences for either of the
actions Q0(a) [40, 41]. The optimal solution for a ratio-
nal yet constrained decision follows (see SI),
Q(a) =
1
Z
Q0(a)e
βUa (2)
5where Z =
∑
aQ0(a)e
βUa is a normalization factor and β
is the efficacy of information processing. As β increases,
a rational decision-maker more readily chooses the action
with the highest utility. Moreover, if the prior distribu-
tion is uniform across actions (i.e., no prior preference),
rational decisions follow a maximum entropy distribution
Q(a) ∼ exp[βUa] [42], which we will use in the rest of our
analysis.
A decision to mount a memory or na¨ıve response Q(a)
based on their respective utilities (eq. 2) should be con-
sistent with the biophysical description of the immune
response through recognition of an antigen by either of
these cell types (eq. 1). By equating these two descrip-
tions of an immune response (eqs. 1, 2) we can specify
the utility gain associated with mounting a memory or a
na¨ıve response in terms of the biophysics and kinetic of
receptor-antigen interactions. Importantly, in the regime
that memory is efficient and being used (i.e., P
(m)
recog.  0),
the utility gain by a memory or a na¨ıve response to an
evolved antigen υi at an antigenic distance di = ‖υi−υ0‖
from the memory receptor’s cognate antigen υ∗rm ≡ υ0
follows (see SI),
Umem(‖υi − υ0‖;α, θ) = Una¨ıve + Eα,θ(rm, υi)
= −Ω(Γτ ) + Eα,θ(‖υi − υ0‖)
(3)
Here, we introduce the cost for deliberation Ω(Γτ ) as the
negative utility of the n¨ıve response Una¨ıve. Deliberation
cost Ω(Γτ ) is a monotonically increasing function of the
cumulative pathogen load Γτ and reflects the damage
(cost) incurred by pathogens as they proliferate during
the deliberation time τ prior to activation of the novel
na¨ıve response; see Fig. 1. It is important to note that
the difference in the memory and the na¨ıve utility ∆U =
Umem − Una¨ıve determines the decision to mount either of
these responses.
The same consistency criteria between decision-making
(eq. 2) and cellular recognition (eq. 1) indicates that
the information processing factor β in eq. 2 should be
equal to the accumulated pathogenic load Γ(τ) during
the deliberation period τ : β = Γ(τ). A longer delib-
eration, which on one hand leads to the accumulation
of pathogens, would allow the immune system to exploit
the utility of a usable memory (i.e., process information),
even if the memory has only a slight advantage over a re-
sponsive na¨ıve receptor. As a result, we refer to β as
the deliberation factor. Moreover, this analogy relates
the efficacy of information processing β, which plays the
role of inverse temperature in thermodynamics, and the
total accumulated pathogenic load Γ(υ, τ), which acts as
the sample size for memory receptors as they encounter
and accumulate information about pathogens. Interest-
ingly, previous work has drawn a similar correspondence
between the inverse temperature in thermodynamics and
the effect of sample size on statistical inference [43].
The deliberation factor in the immune system should
be bounded β ≤ βmax in order for the organism to sur-
vive new infections by mounting a novel response that
can suppress an exponentially replicating pathogen be-
fore it overwhelms the host. Using this bound, we define
rescaled deliberation factor βˆ ≡ β/βmax ≤ 1 to character-
ize the kinetics of an immune response in a dimensionless
fashion.
If the immune system decides to mount a memory re-
sponse against an evolved antigen υi, the binding pro-
file of memory against the target pathogen remains un-
changed and equal to the profile Eα,θ(rυ0 , υ) against the
primary infection υ0. However, if the immune system
mounts a na¨ıve response, a new memory receptor rυi
would be generated with a binding profile Eα,θ(rυi , υ),
centered around the latest infection υi. As a result, the
expected binding profile Eˆ
(i)
α,θ(υ) at the i
th round of in-
fection is an interpolation between the profiles associated
with memory and na¨ıve response, weighted by the likeli-
hood of each decision (eq. 1),
Eˆ
(i)
α,θ(υ) = P
(m)
recog.(rυ0 , υi)Eα,θ(rυ0 , υ) +P
(0)
recog.(υi)Eα,θ(rυi , υ)
(4)
The expected binding profile at the ith round of in-
fection Eˆ
(i)
α,θ(υ) (eq. 4) deviates from the optimal pro-
file centered around the infecting pathogen Eα,θ(rυi , υ)
(i.e., memory profile stored following a novel response);
see Fig. 1. This deviation arises because an energeti-
cally sub-optimal memory response can still be favorable
when time is of an essence and the decision has to be
made on the fly with short deliberation. This tradeoff
between the kinetics and the energetics of immune re-
sponse results in a non-equilibrium decision-making [44]
by the immune system. In analogy to non-equilibrium
thermodynamics, we express this deviation as a dissipa-
tive cost of memory response Kdiss(ti;α, θ) at the i
th
round of infection (time point ti), which we quantify by
the Kullback-Leibler distance between the expected and
the optimal binding profiles, in units of the deliberation
factor β,
Kdiss(ti;α, θ) =
1
β
DKL
(
Eˆ
(i)
α,θ(υ)||Eα,θ(rυi , υ)
)
=
1
β
∑
antigens: υ
Eˆ
(i)
α,θ(υ) log
[
Eˆ
(i)
α,θ(υ)
Eα,θ(rυi , υ)
]
(5)
where we ensure that binding profiles are normalized over
the space of antigens. The dissipation Kdiss measures the
sub-optimality (cost) of the mounted response through
non-equilibrium decision-making and quantifies deviation
from an equilibrium immune response [44].
An optimal memory strategy should be chosen such
that it maximizes the expected utility of the immune
response 〈U〉 = UmemP (m)recog. + Una¨ıveP (0)recog., while min-
imizing the dissipation cost due to the non-equilibrium
response Kdiss, over the lifetime of an organism. To infer
an optimal strategy, we introduce net utility Unet that ac-
counts for the tradeoff between the expected utility and
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FIG. 2: Optimal memory strategies against evolving pathogens. (A) and (B) show the optimal rescaled specificity
αˆ∗ ≡ α∗/αmax and rescaled deliberation factor βˆ∗ ≡ β∗/βmax as a function of the rescaled antigenic divergence per infection δˆ =
δ/(α−1max), respectively. (C) and (D) show the scaled net utility Uˆnet ≡ Unet/Emax (eq. 7) and dissipation Kˆdiss ≡ Kdiss/Emax
(eq. 5) per round of infection as a function of the antigenic divergence δˆ. Rescaling by Emax sets the magnitude of net utility
for a response to conserved antigens (with δˆ = 0), and in the limit of zero deliberation cost Ω → 0, to 1. Colors / markers
indicate different na¨ıve cost functions for deliberation, including no-cost Ωˆ ≡ Ω/Emax = 0, linear cost Ωˆ = Ωˆ0βˆ, and quadratic
cost Ωˆ = Ωˆ0βˆ
2, with varying amplitudes. Simulation parameters: αmax = 4, βmax = 10, and θ = 2. Results for other shape
parameters θ and specificity thresholds αmax are shown in Figs. S1, S2, respectively.
dissipation at a given round of infection at time point ti,
Unet(ti;α, β, θ) = 〈Uα,β,θ(ti)〉 −Kdiss(ti;α, θ) (6)
Net utility can be interpreted as the extracted (in-
formation theoretical) work of a rational decision-maker
that acts in a limited time, and hence, is constantly kept
out of equilibrium [44]. We infer the optimal memory
protocol (i.e., the optimal memory specificity α∗ and de-
liberation factor β∗) by maximizing the total net utility
of memory responses throughout the lifetime of an or-
ganism,
(α∗, β∗) = argmax
α,β
∑
i: infections
Unet(ti;α, β, θ). (7)
III. RESULTS
Efficient immune memory balances specificity and
speed. An optimal immune protocol balances the speci-
ficity of memory and deliberation time that it takes to
mount a novel response in a host. On the one hand, a
longer deliberation would allow the immune system to
exploit a stored cross-reactive memory, even with a low
affinity, to recognize an evolved pathogen (eq. 1). On the
other hand, if memory is inefficient, long deliberations
would allow pathogens to further proliferate, incurring
a larger cost Ω to a host prior to activation of a novel
response.
The extent of cross-reactivity and deliberation needed
for the memory to react to pathogens should be set by
the amount of pathogenic evolution and more specifi-
cally, the antigenic divergence δ ≡ √〈‖υi − υi−1‖2〉 that
a pathogen traces between two infections. Therefore, we
set to find an optimal immune protocol (i.e., specificity
α∗ and deliberation β∗) by maximizing the net utility
Unet of an immune system (eq. 7) that is trained to
counter pathogens with a given (scaled) antigenic diver-
gence δˆ ≡ δ/(αmax)−1 over rounds of infection; see SI for
details on the optimization procedure.
We can describe immune strategies in three differ-
ent regimes, corresponding to optimal strategies against
slowly evolving pathogens (δˆ ≤ 20%), moderately evolv-
ing pathogens (δˆ ' 20% − 80%) and extremely rapidly
evolving pathogen (δˆ > 80%).
To battle slowly evolving pathogens (δˆ ≤ 20%) an
optimal immune system stores highly specific memory
receptors, with a specificity that approaches the upper
bound αmax; see Fig. 2A and Figs. S1, S2. Impor-
tantly, the dependency of optimal specificity on anti-
genic divergence is insensitive to the cost of delibera-
tion Ω prior to mounting a na¨ıve response (Fig. 2A),
the shape factor θ for the specificity profile (Fig. S1),
and the specificity threshold αmax (Fig. S2). For rela-
tively conserved pathogens (δˆ ' 0), the highly specific
memory (with αˆ∗ ≡ α∗/αmax ' 1) stored from a pre-
vious infection remains perfect and therefore, immune
system maintains a moderate level of deliberation to ex-
ploit this efficient memory during infections. However,
as antigenic divergence grows, specific memory becomes
less effective against future infections and therefore, the
immune system reduces the deliberation factor to allow a
timely novel response, once memory becomes inefficient
(Figs. 2B, S1, S2). The magnitude of deliberation decays
as the cost of deliberation Ω increases but its overall de-
pendency on antigenic divergence remains comparable for
different cost functions (shown in Fig. 2B for zero cost,
and cost functions that grow linearly and quadratically
with deliberation factor β). Overall, the net utility of the
stored memory in response to slowly evolving pathogens
is high (Figs. 2C, S1, S2), while its dissipation remains
small Kdiss ' 0 (Figs. 2D, S1, S2). Therefore, in analogy
70.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
scaled antigenic divergence, δˆ
0.0
0.2
0.4
0.6
0.8
1.0
sc
a
le
d
d
el
ib
er
a
ti
o
n
fa
ct
o
r,
βˆ
0.0
0.2
0.4
0.6
0.8
1.0
sca
led
n
et
u
tility,
Uˆ
n
et
40% dissipation
boundary
70%
eq
u
il
ib
ri
u
m
m
em
o
ry
non-equilibrium
memory
equilibrium
naive
FIG. 3: Antigenic divergence determines modes of
immune strategies. The heat map shows the expected net
utility Unet (eq. 7) per round of infection for an immune sys-
tem with an optimal specificity αˆ∗, as a function of rescaled
antigenic divergence (per encounter) δˆ and deliberation fac-
tor βˆ. Boundaries indicate different levels of dissipation, with
the orange and blue boundaries encompassing a region with
≥ 40% and ≥ 70% of the maximum dissipation Kmax, respec-
tively. The magnitudes of dissipation and net utility of an
optimal memory classifies immune response to into three in-
dicated modes: (i) equilibrium memory, (ii) non-equilibrium
memory and (iii) equilibrium na¨ıve. Simulation parameters:
linear deliberation cost function Ωˆ = Ωˆ0βˆ with Ωˆ0 = 0.1,
αmax = 4, βmax = 10, and θ = 2.
to thermodynamics, we term this immune strategy with
low dissipation as equilibrium memory response; Fig. 3.
To battle moderately evolving pathogens (with δˆ '
20% − 80%), an optimal immune system stores cross-
reactive memory (i.e., with a lower specificity αˆ) that
can recognize moderately evolved form of the primary
antigen (Figs. 2A, S1, S2). However, cross-reactive re-
ceptors tend to have lower affinities [34, 35], which could
lead to deficient responses against antigens. Importantly,
activation of energetically sub-optimal yet cross-reactive
memory could be detrimental as it may hinder a stronger
novel response without providing protective immunity to
the host— a deficiency known as the original antigenic
sin [45, 46]. An optimal immune system can mitigate this
problem by using kinetic optimization to tune the delib-
eration factor β in order to avoid an elongated mem-
ory engagement prior to a na¨ıve response. This opti-
mization results in a smaller deliberation factor β (i.e.,
a faster na¨ıve response) compared to the scenario with
slowly evolving pathogens, yet a long enough deliber-
ation to allow the energetically suboptimal memory to
react to an infection, whenever feasible (Figs. 2B, S1,
S2). With this kinetic optimization, the immune sys-
tem can utilize cross-reactive memories through multiple
rounds of infection (Fig. S3), yet with a declining net
utility as pathogens evolve away from the primary in-
fection (Figs. 2C, S1, S2). The prominent memory re-
sponse to moderately evolving pathogens is dissipative
with Kdiss  0 (Figs. 2D, S1, S2), and in analogy with
thermodynamics, we term this dissipative immune strat-
egy as non-equilibrium memory response; Fig. 3.
For extremely rapidly evolving pathogens (δˆ > 80%),
the immune system would not be able to store an efficient
memory to battle future encounters, and hence, each in-
fection would trigger a novel na¨ıve response — the re-
duced net utility of memory and the decay of memory
usage in this regime are shown in Figs. 2C, S1, S2, and
Fig. S3, respectively. Without a protective memory, a
novel response is triggered to counter each infection and
it maturates specifically around the infecting pathogen,
resulting in a non-dissipative na¨ıve-dominated immune
response with Kdiss ' 0, which we term equilibrium na¨ıve
response; Fig. 3.
It should be noted that when the cost of deliberation
Ω is very high, utilizing memory against pathogens
with relatively high evolutionary rates becomes highly
unfavorable. In this extreme case, the immune system
switches into a state where it invariably mounts a novel
response upon an infection (Fig. S3), and it assures that
memory is not utilized by setting the parameters for
specificity α and deliberation β to zero (Fig. 2A, B).
Optimal memory production is regulated to store
receptors with intermediate affinity and cross-
reactivity. The results shown in Figs. 2, 3 indicate that
a rational decision to become a memory or a plasma cell
during an immune response should depend on the affin-
ity of a cell’s receptors and it should not be a stochastic
choice with a constant rate throughout affinity matura-
tion. Indeed, cell fate decision for B-cells during affinity
maturation is highly regulated and dependent on recep-
tors’ affinity [1, 2, 16, 47–49]. Recent experiments have
demonstrated that memory generation is highly corre-
lated with the activity of the transcription factor Bach2
whose expression level is negatively regulated with the
abundance of helper CD4+ T-cells [1, 2, 48]. As the
affinity of B-cell receptors increases during affinity mat-
uration, more CD4+ T-cells are recruited to germinal
centers, resulting in suppression of Bach2 and a hence,
a decline in production of memory cells [1, 2, 48]. In
other words, our adaptive immune system has encoded a
negative feedback mechanism to store memory with in-
termediate affinity and cross-reactivity to suppress the
production of highly specific memory, which is likely to
be impotent against evolved pathogens in future infec-
tions.
In addition, Figs. 2, 3 also show that an optimal
immune system should provide a deliberation time for
a cross-reactive memory to mount an immune response,
before activation of novel response. This prediction
is also in accordance with the kinetics of immune
response, where if available, memory can react and
become effective by about τ ≈ 1.5 − 5 days faster than
a novel adaptive immune response [9, 10, 32]. This
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with distinct evolutionary rates. Distribution of scaled
optimized specificities αˆ∗ for functional memory (purple) is
shown for an immune system with a fixed deliberation factor
βˆ = 0.2, in which a mixture strategy with a bimodal distribu-
tion of specificities P (αˆ) is established to counter pathogens
with a broad range of antigenic divergences. The dashed bar
indicates stored memory with specificity α = 0, which is not
further used in response to infections. The solid line indicates
the probability Pusage that a stored memory with a given
specificity is utilized in future infections (SI). Optimization
is done by maximizing the net utility of immune response
averaged over encounters with 1000 independently evolving
antigens with (scaled) antigenic divergences drawn uniformly
from a range δˆ ∈ (0, 1.6) (SI). The distribution shows the en-
semble statistics of functional memory accumulated from 200
independent optimizations, each starting from a flat prior for
specificities (orange). The insert shows the optimized mixture
strategy for one optimization with 3000 steps. Simulation pa-
rameters: αmax = 4, βmax = 10, and θ = 2.
deliberation time provides a window for cross-reactive
(and lower affinity) memory to recognize an antigen
and initiate a downstream cascade of immune reactions.
Indeed, if such deliberation were not programmed in the
immune system, memory storage would become futile
after only a few rounds of encounters with an evolved
pathogen. The fact that the adaptive immune system
has set up machinery with intermediate specificity αˆ
and deliberation factor βˆ suggests that this immune
strategy has undergone evolutionary optimization to
battle evolving pathogens.
A mixture of memory isotypes is necessary to
counter pathogens with a broad range of evolu-
tionary rates. The decision to trigger an equilibrium
or a non-equilibrium memory response depends on the
extent of antigenic divergence that an immune system
is trained to cope with (Figs. 2, 3, S1, S2). Equilib-
rium memory is highly effective (i.e., it has high net util-
ity) against relatively conserved pathogens, however, it
fails to counter evolving pathogens (Fig. 2C). On the
other hand, cross-reactive non-equilibrium memory is
more versatile and can counter a broader range of evolved
pathogens but at a cost of reduced net utility in immune
response; Figs. 2C, 3, S1, S2.
An optimal immune system should have memory
strategies to counter pathogens with varying evolutionary
rates, ranging from relatively conserved pathogens like
chickenpox to rapidly evolving viruses like influenza. We
use our optimization protocol to find such memory strate-
gies that maximize the net utility of an immune system
that encounters evolving pathogens with antigenic diver-
gences uniformly drawn from a broad range of δˆ ∈ [0 1.6];
see SI. This optimization results in a bimodal distribution
of optimal specificity for functional memory receptors
P (α), with separated peaks corresponding to equilibrium
(αˆ ∼ 1) and non-equilibrium (αˆ ∼ 0.5) memory (Figs. 4,
S4). This result suggests that specific and cross-reactive
memory strategies are complementary modes of immune
response that cannot substitute each other. Moreover,
non-equilibrium memory tends to be flexible and mod-
erate values of cross-reactivity 1/αˆ can counter a broad
range of antigenic divergences, without a need for fine-
tuning. Therefore, upon production of memory, an opti-
mal immune system should harvest both specific equilib-
rium memory and cross-reactive non-equilibrium mem-
ory, as it does not have a priori knowledge about the
evolutionary rate of the infecting pathogen.
Interestingly, our adaptive immune system stores a
mixture of IgM and class-switched IgG isotypes of B-cell
memory that show different levels of specificity. IgM
memory is an earlier product of affinity maturation with
higher cross-reactivity and a lower affinity to antigens,
reflecting a non-equilibrium memory that can counter
evolving pathogens. On the other hand, memory from
class-switched IgG isotype is produced during later
stages of affinity maturation and is highly specific to the
infecting pathogen, reflecting equilibrium memory that
is effective against relatively conserved pathogens [16].
Storing a mixture of IgM and class-switched IgG mem-
ory is consistent with our recipe for optimal immune
strategies to counter pathogens with a broad range of
evolutionary rates.
Cross-reactive memory dominates immune re-
sponse in organisms that encounter fewer
pathogens over a shorter lifetime. So far, our anal-
ysis has focused on maximizing the net utility of immune
response, assuming that organisms encounter many such
infections throughout their lifetime. This optimization
provides a recipe for optimal immune strategies in re-
sponse to commonly infecting pathogens. However, the
expected frequency of infections is also an important fac-
tor that can inform immune strategies. For example,
imagine the extreme case that an immune system ex-
pects to encounter a pathogen at most only once during
an organism’s lifetime, e.g. in short-lived organisms. In
this case, there is no benefit in keeping a memory even to
counter extremely conserved pathogens, for which mem-
ory would be otherwise very beneficial.
To study the impact of infection frequency on immune
strategies, we use our optimization procedure to maxi-
mize the net utility of immune response, while setting a
bound on the number of infections throughout an organ-
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ism’s lifetime (see SI).
Organisms with an unrealistically very short lifetime
(measured in units of the number of infections) experi-
ence only a few infections, and therefore, a small anti-
genic drift from the primary infection (lifetime < 8 in
units of the number of infections, in Fig 5A). In this case,
it would be sufficient for an optimal immune system to
generate specific memory (αˆ ≈ 1), which can mount an
effective response with only an intermediate deliberation
(βˆ ∼ 0.4) upon reinfection, even against pathogens with
a moderate evolutionary rate (Fig 5A). Organisms with
moderately short lifetime experience evolutionary diver-
gence of reinfecting antigens. In this regime, the immune
system stores cross-reactive memory (smaller αˆ) and uses
a larger deliberation factor βˆ such that this lower-affinity
and often off-centered memory can mount an effective re-
sponse to evolved infections (Fig. 5A). Since the organ-
ism is relatively short lived, such cross reactive memory
could be sufficient throughout the whole lifetime of the
organism, without a need for renewal. As the number
of encounters passes a threshold c∗ (longer lifetime), an
optimal immune strategy switches from storing and uti-
lizing cross-reactive memory to generating more specific
memory receptors, which would be continually renewed
during organisms’ lifetime (Fig. 5A). In this regime, the
deliberation factor also decreases to facilitate novel re-
sponses against antigens that are not readily recognized
by memory (Fig 5A). The transition threshold c∗ depends
on the expected antigenic divergence δ during pathogenic
evolution and the details of the immune machinery, and
specifically the cost of deliberation Ω(τ) due to an ele-
vated level of pathogenic proliferation prior to a novel
response (see Fig 5B).
The results in Fig. 5 predict that organisms with few
pathogenic encounters or a shorter life-span should gen-
erate more cross-reactive and lower affinity (i.e., a na¨ıve-
type) memory receptors. Indeed, consistent with our pre-
diction, analysis of immune repertoire data indicates that
sequence features of memory and na¨ıve B-cell receptors
tend to be more similar to each other in mouse com-
pared to humans that enjoy a longer life expectancy [50].
Nonetheless, more comprehensive data on cross-species
comparison of immune strategies is needed to test our
predictions.
With the increase in human life expectancy, a press-
ing question is how well our immune system could cope
with a larger number of pathogenic challenges that we
are now encountering throughout our lifetimes? Aging
has many implications for our immune machinery and
the history of infections throughout lifetime leaves a com-
plex mark on immune memory that can have long-lasting
consequences [51], which has also been studied through
theoretical modeling [28]. In our framework, we can
study one aspect of this problem and ask how an im-
mune strategy optimized to battle a given number of in-
fections would perform if the organism were to live longer
or equivalently, to encounter pathogens more frequently.
Fig. 5C shows that cross-reactive memory generated by
an immune system optimized to counter few infections
(short life expectancy) becomes highly inefficient (i.e.,
with a lower net utility Unet) as the number of encoun-
ters increases beyond the organism’s expectation (long
life span) — an effect that may be in part responsible
for the observed decline in the efficacy of our adaptive
immunity as we age.
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IV. DISCUSSION
Memory is central to our adaptive immunity by pro-
viding a robust and preventive response to reinfect-
ing pathogens. In the presence of continually evolving
pathogens, immune memory is only beneficial if recep-
tors can recognize evolved antigens by cross-reactivity.
As receptors undergo affinity maturation, their struc-
tures become more rigid and less cross-reactive, while
affinity increases [34, 35]. Consistent with recent exper-
iments [1, 2, 16, 17], we show that memory differentia-
tion should be regulated to preferentially produce lower
affinity receptors, which can allow cross-reactive recog-
nition of evolved pathogens. To overcome the resulting
energetic impediment of these memory receptors, we in-
fer that the immune system should tune the kinetics of
the immune response and allocate a longer deliberation
time for memory to react before initiating a novel re-
sponse — a feature that is also in accordance with obser-
vations [9, 10, 32]. Co-optimizing kinetics and energetics
of memory ensures an effective response against evolving
pathogens, throughout an organism’s lifetime.
Optimal cross-reactive immune memory provides a
long-term advantage to an organism, yet it may seem
energetically sub-optimal over short time scales (Fig. 1).
One important consequence of a sub-optimal memory re-
sponse is known as original antigenic sin, where cross-
reactive memory from primary infections could interfere
with and suppress a protective novel response [45, 46] —
a deficiency that is highly relevant for immunity against
rapidly evolving viruses like influenza. The impact of
such immune deficiency can even be more pronounced
due to changes in an organism’s life expectancy. Impor-
tantly, we show that immune strategies optimized to ben-
efit short-lived organisms produce highly cross-reactive
memory (Fig. 5). If an organism’s life-expectancy in-
creases, which is the case for humans, it would be likely
for individuals to encounter evolved forms of a pathogen
at antigenic distances larger than expected by their im-
mune systems. In this case, cross-reactive memory op-
timized for a shorter lifetime, could still be activated
but with lower efficacy and it could suppress a protective
novel response, consistent with original antigenic sin. It
is therefore important to consider sub-optimality of im-
mune strategies in the face of extensive elongation of the
human lifespan as one of the plausible factors responsible
for immune deficiencies brought by aging.
One characteristic of memory B-cells, which is cur-
rently missing from our model, is their ability to seed
secondary germinal centers and undergo further affinity
maturation upon reinfection. Evolvability of memory
B-cells can allow cross-reactive memory to further
specialize against evolved pathogens, without a need to
start a germinal center reaction from an un-mutated
na¨ıve receptor. Interestingly, different experiments
suggest that the capacity of memory to re-diversify
depends on various factors including the memory isotype
(IgM vs. class-switch receptors), the type of antigenic
target (viruses vs. others) and the extent of memory
maturation [38, 39]. Therefore, it is interesting to extend
our model to study how evolvability of memory can
influence its longterm utility to respond to evolving
pathogens, and especially viruses. Understanding the
limits of memory re-diversification is instrumental in
designing successive vaccination protocols to drive
extensive affinity maturation of BCR lineages to elicit
broadly neutralizing antibodies, which are the current
hopes for universal vaccines against rapidly evolving
viruses like HIV.
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Supplementary Information
i. Numerical optimization
Numerical optimization is performed on ensembles of immune systems that encounter evolving pathogens. Recog-
nition of an evolved pathogen at the ith round of infection υi by a memory that was stored in response to a primary
infection υ0 (0
th round) depends on the antigenic distance di = ‖υi−υ0‖. We model pathogenic evolution as diffusion
in the antigenic shape space. In this model, the expected antigenic distance between the primary infection υ0 and
the evolved antigen υi can be characterized as, 〈d2i 〉 ≡ 〈‖υi − υ0‖2〉 = ζ2(ti − t0) = i δ2, where ζ is the diffusion coef-
ficient (i.e., the evolutionary rate) and δ is the (averaged) antigenic divergence per round of infection. Importantly,
this relationship does not depend on the dimensionality of the antigenic shape space, which in general, is difficult to
characterize. We simulate pathogenic evolution relative to a primary infection by drawing the corresponding antigenic
distance di of the i
th round of infection from a normal distribution with mean δ
√
i and standard deviation 0.05δ
√
i.
The width of this normal distribution characterizes the fluctuations in the mean divergence between infections and
reflects how the evolutionary trajectory of a pathogen samples the multi-dimensional shape space surrounding the
antigen from the primary infection. Nonetheless, our results are insensitive to the exact choice of this width.
To characterize optimal specificity α∗ and deliberation factor β∗ (Figs. 2,3,5), we simulate ensembles of immune
systems with different immune strategies (α, β), chosen uniformly from the range α ∈ [0, αmax] and β ∈ [0, βmax],
with 500 increments in both parameters. Each immune system experiences successive rounds of infection with an
evolving pathogen with a given antigenic divergence δ. During each encounter, the immune system chooses between
utilizing an existing memory or initiating a novel response according to eq. 2. The net utility of each encounter is
calculated according to eq. 6. We estimate the expected net utility per encounter over a lifetime of 60 total encounters
and repeat this experiment across 105 independent ensembles to find the optimal immune strategies (α∗, β∗) with the
highest net utility. As shown in Fig. 5, simulating up to 60 encounters is sufficient for inference of optimal strategies
in the asymptotic regime (i.e., a long lifetime).
To characterize optimal immune strategies against mixture of pathogens with distinct levels of antigenic divergences,
we define the mixture immune strategy by a set of specificities ~α = {αi} = (with, i = 1, . . . , Nm), where each αi is a
degree of specificity that a stored memory receptor can potentially have, and Nm is the number of possible specificity
strategies that an immune system can choose from. The probability that an immune system with the mixture strategy
~α recognizes a pathogen υ through a memory response follows from an extension of eq. 1,
P (m)recog.(~α, υ) = 1−
∏
specificity: αi
(
1− P (m)recog.(rαim , υ)
)
= 1−
∏
specificity: αi
e−Eθ(r
αi
m ,υ)Γ(τ) = 1− e−
∑
αi
Eθ(r
αi
m ,υ)Γ(τ) ≡ 1− e−β˜ Eθ(υ) (S1)
where Eθ(υ) =
1
Nm
∑
rαm
Eθ(r
αi
m , υ) is the expected affinity of memory (with distinct specificities) against antigen υ in
an immune repertoire and β˜ ≡ Nmβ is an effective deliberation factor for all choices of specificity. It should be noted
that this effective deliberation factor β˜ is an extensive quantity with respect to the number of specificity strategies
that an immune system can choose from, and therefore, is comparable across immune systems with different numbers
of strategies.
We set out to characterize the mixture strategy as the probability Pβ(α) based on which an immune system with a
given effective deliberation factor β˜ should store a memory receptor with specificity α, in order to optimally counter
infecting pathogens with distinct antigenic divergences, drawn from a distribution P (δ). We start our optimization by
defining a uniform mixture strategy, where the elements of the immune specificity vector ~α = {αi} (of size Nm = 20),
are drawn uniformly from the range [0, αmax]. Each optimization step aims to improve the specificity vector ~α
to maximize the net utility (per encounter) of the mixture immune response Unet(~α
k) against 1000 independently
evolving antigens whose (scaled) antigenic divergences are drawn uniformly from the range δˆ = [0, δˆmax]. We use
stochastic simulations to estimate the net utility of the mixture strategy Unet(~α
k), whereby the relative affinity of
memory receptors (with varying specificities), Eθ(r
αi
m , υ)/Eθ(υ), determines the stochastic rate of their response to
the infecting antigen υ. The net utility (per encounter) of the immune response against each of the 1000 independently
evolving antigens is estimated by averaging over a host’s lifetime with 200 rounds of pathogenic encounters. We update
the mixture strategy over 3000 steps, using local gradient ascent by sampling 100 points in the space of specificity
vectors at each step to maximize net utility,
~αk+1 = ~αk + ∇Unet(~αk) (S2)
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Here, k indicates the optimization step and  = 0.1 is a hyper-parameter for gradient ascent. We repeat the op-
timization process starting from 200 independently drawn initial uniform mixture strategies ~α 0 to characterize the
ensemble of optimal memory strategies Pβ(α) against pathogens with distinct antigenic divergences drawn uniformly
from a given range δˆ = [0, δˆmax], as shown in Fig. 4. We also characterize the probability that a stored memory with
a given specificity is utilized against future infections (solid line in Fig. 4). To do so, we test the optimized ensemble
of specificities Pβ(α) against 5000 independent pathogens with antigenic divergences drawn uniformly from the range
δˆ = [0, δˆmax]. We evaluate the usage of a memory with a given specificity α (solid line in Fig. 4) as the conditional
probability Pβ(use α|produce α) for using that memory given that it is produced (i.e., drawn from the distribution
Pβ(α)).
ii. Decision-making for immune response
In the theory of decision-making, a rational decision-maker chooses between two possible actions a ∈
{na¨ıve, memory} each contributing a utility Ua. If the decision-maker has different prior preference for each ac-
tion, which we denote by the prior probability distribution Q0(a), its decisions could be swayed by this knowledge.
As a result, the constrained decision-maker should choose actions according to an optimized probability density Q(a),
which maximizes the expected utility while satisfying constraints due to the prior assumption [40, 41],
Q(a) = argmax
Q(a)
(∑
a
UaQ(a)− 1
β
DKL (Q(a)||Q0(a))
)
(S3)
Here, DKL(Q(a)||Q0(a)) =∑aQ(a) log (Q(a)/Q0(a)) is the Kullback-Leibler distance between the rational distribution
Q(a) and the prior distribution Q0(a) and 1/β is a Lagrange multiplier that constrains the efficacy of a decision-maker
to process new information and deviate from its prior assumption. The optimal solution for a rational yet constrained
decision follows,
Q(a) =
1
Z
Q0(a)e
βUa (S4)
where Z =
∑
aQ0(a)e
βUa is a normalization factor. If information processing is highly efficient (i.e., the bias factor
1/β → 0) the rational decision-maker deterministically chooses the action with the highest utility. On the other hand,
if the prior is strong (i.e., 1/β → ∞), the decision-maker hardly changes its opinion and acts according to its prior
belief (i.e., Q(a) = Q0(a)). Moreover, if the prior distribution is uniform across actions (i.e., no prior preference),
rational decision maximizes the entropy of the system [42], resulting in the probability of actions Q(a) ∼ exp[βUa].
In our analysis we consider the case of unbiased maximum entropy solution for decision-making. As a result the
probability to utilize memory Qmem. or na¨ıve Qna¨ıve follows,
Qmem. = 1−Qna¨ıve = e
βUmem
eβUmem + eβUna¨ıve
(S5)
which is a sigmoidal function, dependent on the utility of each action.
We can draw an analogy between the two description of memory response that are based on (i) recognition of a
pathogen by considering the energetics and kinetics of the immune response (eq. 1) and (ii) the rational decision-
making by considering the utility and the efficacy of decision-making (eq. S5). By equating these two descriptions we
have,
Qmem. = P
(m)
recog.(rm, υ) −→
eβUmem
eβUmem + eβUna¨ıve
= 1− e−Eα,θ(rm,υ)Γ(υ,τ)
−→ β(Umem. − Una¨ıve) = log
[
eEα,θ(rm,υ)Γ(υ,τ) − 1
]
(S6)
In the regime that memory is efficient and is being utilized to mount a response (i.e., a low chance for na¨ıve recognition:
P
(0)
recog. = e−E(υ)Γ(υ,τ)  1), the sigmoid form for decision to use memory (eq. S5) is dominated by an exponential
factor, resulting in a simple analogy: β ' Γ(υ, τ), and Umem. − Una¨ıve ' Eα,θ(rm, υ).
Previous work has drawn a correspondence between the inverse temperature in thermodynamics and the effect of
sample size on statistical inference [43]. Interestingly, we see a similar analogy between the efficacy of information
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processing in decision-making (i.e., deliberation factor) β, which plays the role of the inverse temperature in thermo-
dynamics, and the total accumulated pathogenic load Γ(υ, τ), which acts as the sample size for memory receptors as
they encounter and accumulate information about pathogens.
It should be noted that our decision-making formalism assumes that if memory is available, it can be utilized much
more efficiently and robustly than a na¨ıve response. Therefore, we do not consider scenarios where memory and
na¨ıve responses are equally involved in countering an infection— a possibility that could play a role in real immune
responses. Nonetheless, since such mixed responses are relatively rare, we expect that including them in our model
would only result in a slightly different interpretation of the deliberation factor β and should not qualitatively impact
our results.
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FIG. S1: Optimal memory strategies for different specificity shape factors θ. (A) Scaled specificity αˆ∗ ≡ α∗/αmax,
(B) scaled deliberation factor βˆ∗ ≡ β∗/βmax, (C) scaled net utility Uˆnet ≡ Unet/Emax, and (D) scaled dissipation are shown
as a function of the scaled antigenic divergence per infection δˆ = δ/(α−1max) (similar to Fig. 2). Colors indicate different shape
factors θ of the specificity function, ranging from a double-sided exponential (θ = 1), to Gaussian for θ = 2 (as in Fig. 2), and
top-hat functions θ > 2. The dependence of memory strategies on antigenic divergence is qualitatively insensitive to the shape
factor of the specificity function. Simulation parameters: linear deliberation cost function Ω = Ωˆ0βˆ with Ωˆ0 = 0.1, αmax = 4,
and βmax = 10.
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FIG. S2: Optimal memory strategies for different specificity thresholds αmax. (A) Scaled specificity αˆ
∗ ≡ α∗/αmax,
(B) scaled deliberation factor βˆ∗ ≡ β∗/βmax, (C) scaled net utility Uˆnet ≡ Unet/Emax, and (D) scaled dissipation are shown as
a function of the scaled antigenic divergence per infection δˆ = δ/(α−1max) (similar to Fig. 2). Colors indicate different specificity
thresholds αmax. Memory strategies are qualitatively insensitive to the specificity threshold. Simulation parameters: linear
deliberation cost function Ω = Ωˆ0βˆ with Ωˆ0 = 0.1 and βmax = 10.
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FIG. S3: Rounds of memory usage depends on antigenic divergence. The expected number of rounds that a memory
receptor is utilized prior to a novel response in an optimal system is shown to decay as the antigenic divergence δˆ increases. The
results are evaluated for immune systems with optimized strategies (αˆ∗, βˆ∗) against pathogens with a given scaled antigenic
divergence δˆ; the corresponding strategies are shown in Fig. 2. Colors / markers indicate different na¨ıve cost functions for
deliberation, including no-cost Ωˆ ≡ Ω/Emax = 0, linear cost Ωˆ = Ωˆ0βˆ, and quadratic cost Ωˆ = Ωˆ0βˆ2, with varying amplitudes
Ωˆ0. Simulation parameters: αmax = 4, βmax = 10, and θ = 2.
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FIG. S4: Mixed memory strategy against pathogens for different deliberation factors βˆ. Distribution of scaled
optimized specificities αˆ∗ of functional memories is shown for an immune system with a fixed deliberation factor βˆ = 0.2, in
which a mixture strategy with a bimodal distribution of specificities P (αˆ) is established to counter pathogens with a broad
range of antigenic divergences, drawn uniformly from a range δˆ ∈ (0, 1.6) (similar to Fig 4). The dashed bars indicate stored
memory with specificity α = 0, which is not further used in response to infections. Colors indicate different deliberation factors.
Simulation parameters: αmax = 4, and βmax = 10.
